Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Retatrutide Half-Life & Pharmacokinetics: 6-Day Decay Curve
articleThe definitive guide to retatrutide (reta) pharmacokinetics: approximately 6 days half-life from the Phase 1b trial (Lancet 2022), about 97% gone after 5 half-lives (30 days, by half-life arithmetic), and about 4 weeks to steady state per dose level (estimated from the half-life). Includes half-life comparison to tirzepatide and semaglutide, dosing implications, and FAQ.
Pharmacokinetics Methodology: How GLP3Planner Models Drug Levels
referenceHow GLP3Planner's calculators model drug levels: a one-compartment model with first-order absorption and elimination (the Bateman function), plotted as milligrams in the body. Each parameter is listed with its source, the assumptions are marked, and the page explains the concentration estimate in the hourly table. Also covers the reconstitution math and the standard titration ladders.
Retatrutide Steady State Chart: Week-by-Week Accumulation
articleHow retatrutide drug levels build week over week toward steady-state plateau. A model-derived accumulation chart per dose level, why the 4-week titration hold matches the pharmacokinetics, and the practical implications for evaluating each dose.